Exosome & EV CDMOs — Ranked by Signal Score

Best Clean FDA History Commercial Scale

CDMOs tracked

Fully scored

With FDA records

FDA inspections

Exosome and extracellular vesicle (EV) CDMOs manufacture next-generation delivery vehicles for RNA, proteins, and small molecules. As an emerging modality, the field is still standardizing cell-source, isolation, and potency methods.

Choosing an exosome CDMO turns on cell-source and culture scale, isolation method (TFF, chromatography), characterization, and a clean regulatory record. The rankings below score each CDMO on FDA inspections, GMP certification, clinical activity, and capacity.

FDA inspection outcomes across these CDMOs: 1 NAI (no action), 0 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: United States (1).

Last updated 2026-07-06. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

#	CDMO	Signal Score	Quality	FDA · GMP	Capacity	Programs
1	CK Codiak BioSciences (Sarepta) Cambridge, MA	78.0	100.0	1 insp · 0 GMP	—	16 programs
2	EA Esco Aster Singapore, SG	63.0	—	—	—	0 programs
3	CoJourney Inc. Ambler, PA (US operations; primary manufacturing in Hangzhou, Zhejiang, China)	60.0	—	—	Limited	0 programs
4	EV Evox Therapeutics Oxford, UK	57.5	—	—	—	0 programs
5	EXO ExoXpert (EXO Biologics) Liege, BE	56.5	—	—	—	0 programs
6	EP Exopharm Melbourne, AU	56.5	—	—	—	0 programs
7	CLB Clara Biotech Indianapolis, IN	56.5	—	—	—	0 programs
—	Cellipont Bioservices The Woodlands, TX	Profiled	—	—	—	0 programs
—	Porton Advanced Cranbury, NJ (US HQ); GMP manufacturing sites in Suzhou, China	Profiled	—	—	—	0 programs

How we score CDMOs →

What to evaluate in a Exosome / Extracellular Vesicle CDMO

Cell source & scale

Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.

Isolation & purification

Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.

Characterization & potency

EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.

Regulatory track record

Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.

Exosome / Extracellular Vesicle CDMOs — Frequently Asked Questions

Who are the top Exosome / Extracellular Vesicle CDMOs?

By CDMO Signal's independent Signal Score, the top-ranked Exosome / Extracellular Vesicle CDMOs include Codiak BioSciences (Sarepta), Esco Aster, CoJourney Inc.. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.

How many Exosome / Extracellular Vesicle CDMOs have FDA inspection records?

CDMO Signal tracks 1 Exosome / Extracellular Vesicle CDMO with FDA inspection records and 0 EMA/MHRA GMP certificates across the group.

What should I look for in an exosome CDMO?

Confirm cell source and scalable culture, a robust isolation method (TFF or chromatography), qualified characterization and potency analytics, and a clean FDA and EMA/MHRA record.

Is exosome manufacturing standardized?

Not yet fully — cell-source, isolation, and potency methods are still maturing across the field, so a CDMO's specific platform and analytics maturity matter more than in established modalities.

Related modalities

mRNA / LNP CDMOs Cell Therapy CDMOs Biologics / mAb CDMOs

Other Modalities

AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Recombinant Proteins ADC